NCT00001148

Brief Summary

Glioblastomas, the most frequent malignant brain tumor in adults, are widespread in the brain, despite their discrete appearance on computed tomography (CT) or magnetic resonance imaging (MRI). While this tumor tends to spread widely in the brain, unlike other tumors of the body, it rarely metastasizes, or spreads, to other organs. Approximately 10 percent of patients with glioblastoma develop metastatic disease after radiation or brain surgery. In the absence of radiation or brain surgery, few patients have developed disease spread outside the brain. During surgery to remove tumors of other organs of the body, such as the lung, prostate, kidney, or ovary, cells from these tumors are routinely found in the bloodstream. These cells are believed to be the reason for the spread of these tumors. In the case of malignant brain tumors, this process of glioma (tumor) cells shedding into circulation has not yet been investigated. This study will determine whether glioma cells can be detected in the bloodstream of patients undergoing surgery. If glioma cells are absent, it may mean they are unable to penetrate the blood-brain barrier. If they are present, they presumably can penetrate into blood vessels but they may be recognized and eliminated by the immune system, or they may escape detection yet not be able to take hold in the new microenvironment. The results of the study will add to the knowledge of the biology of these highly malignant tumors. Study participants will be admitted to the hospital for 8 to 10 days. They will undergo a complete physical and neurological exam and blood and urine tests. An electrocardiogram will be performed, and x-rays may be taken. On the morning of surgery, the patient will receive sedation intravenously. A tiny plastic tube called a catheter will be introduced into a vein in the groin through needles. The catheter will be passed through to the jugular bulb, right above the jugular vein, on the same side as the tumor. The patient will then be taken to the operating room for surgery. During surgery, not more than one quarter of a unit of blood will be removed through the catheter. The catheter will be removed before the patient enters the intensive care unit. Another MRI will be taken after surgery. The study will enroll participants for 2 years. Patients will be followed at 3 months and 6 months after the surgery to make sure the postoperative period is uneventful.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 1999

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 1999

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

November 3, 1999

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 4, 1999

Completed
5.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2005

Completed
Last Updated

March 4, 2008

Status Verified

January 1, 2005

First QC Date

November 3, 1999

Last Update Submit

March 3, 2008

Conditions

Keywords

MetastasisGliomaVenousSamplingp53 MutationGlioblastoma MultiformeCirculating Tumor CellsMutationAnaplastic Astrocytoma

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients must be diagnosed with biopsy-proven glioblastoma multiforme or anaplastic astrocytoma (WHO grade III and IV, WHO classification of glial tumors) and meet the following criteria:
  • Consenting males and females between the ages of 18 and 75, inclusive.
  • Provided written informed consent prior to participation in the trial.
  • Karnofsky Performance Scale Score greater than or equal to 60.
  • Patients of all races and sexes are eligible for this study. Children and adolescents only rarely are afflicted with gliomas that are amenable for surgical resection, and so are excluded from this study.
  • Patients who have been accepted for glioma resection under existing NINDS protocols are also eligible for this study.
  • If tumor tissue is available from biopsy prior to surgery, we will attempt to identify tumor-specific mutation(s) prior to enrolling the patient.

You may not qualify if:

  • Clinically unstable condition.
  • Liver function impairment (total bilirubin greater than 2.0 mg/dl; AST or ALT greater than 3 times the upper limit of normal).
  • Coagulopathy (prothrombin time \[PT\] or activated partial thromboplastin time \[APTT\] \> 1.5 times control).
  • Thrombocytopenia (platelet count less than 100,000/mm3).
  • Granulocytopenia (absolute neutrophil count less than 1,000/mm3).
  • Acute infection.
  • Acute medical problems.
  • Positive HIV test.
  • Karnofsky Performance Scale Score less than 60.
  • Allergy to CT contrast agents.
  • Absence of tumor-specific gene mutation.
  • Pregnant women. Women of child-bearing potential will undergo a urine and/or serum pregnancy test. Women who are pregnant will not be allowed to participate in this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institute of Neurological Disorders and Stroke (NINDS)

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

  • Bernstein JJ, Woodard CA. Glioblastoma cells do not intravasate into blood vessels. Neurosurgery. 1995 Jan;36(1):124-32; discussion 132. doi: 10.1227/00006123-199501000-00016.

    PMID: 7708148BACKGROUND
  • Brew BJ, Garrick R. Gliomas presenting outside the central nervous system. Clin Exp Neurol. 1987;23:111-7.

    PMID: 2822301BACKGROUND
  • Chretien F, Gray F, Funalot B, Authier FJ, Peltier E, Lange F, Degos JD, Poirier J. [Extracerebral metastases of a glioblastoma, in the absence of surgery]. Arch Anat Cytol Pathol. 1995;43(5-6):342-9. French.

    PMID: 8729851BACKGROUND

MeSH Terms

Conditions

AstrocytomaGlioblastomaGliomaNeoplasm MetastasisNeoplastic Cells, Circulating

Condition Hierarchy (Ancestors)

Neoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Sponsor Type
NIH

Study Record Dates

First Submitted

November 3, 1999

First Posted

November 4, 1999

Study Start

October 1, 1999

Study Completion

January 1, 2005

Last Updated

March 4, 2008

Record last verified: 2005-01

Locations